Side-by-side · Research reference
HCGvsVIP
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED12/52 cited
BPhase 3HUMAN-REVIEWED9/42 cited
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
VIP
Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)
IV infusion · Inhaled (investigational)Brown 2023Boesing 2022
01Mechanism of Action
Parameter
HCG
VIP
Primary target
LH receptors on testicular Leydig cellsSchröder-Lange 2025
VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025
Pathway
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection
Downstream effect
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration
Feedback intact?
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
Yes — exogenous VIP acts as physiological agonist
Origin
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP
Antibody development
Rare with recombinant; possible with urinary-derived formulations
—
02Dosage Protocols
Parameter
HCG
VIP
Hypogonadotropic hypogonadism (monotherapy)
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
—
Combined therapy (hCG + FSH)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
—
Triple therapy (experimental)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
—
Cryptorchidism (pediatric)
500–4,000 IU IM 2–3×/week for 3–6 weeks
—
Evidence basis
RCT / Meta-analysis / FDA-approvedKonsam 2026Huijben 2026
Phase 3 RCT (TESICO)Brown 2023
816-patient randomized controlled trial in COVID-19 ARDS.
Duration to sperm appearance
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
—
Monitoring
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
—
Intravenous (ARDS protocol)
—
60–90 mcg/kg/day via continuous infusion
TESICO trial protocol for COVID-19 ARDS.
Inhaled (investigational)
—
Variable dosing under clinical trial protocolsBoesing 2022
Delivered via nebulizer for direct pulmonary deposition.
Treatment duration
—
3–14 days (acute ARDS)
Reconstitution
—
Lyophilized powder reconstituted with sterile diluent per protocol
Half-life
—
~2 minutes (plasma)
Rapid clearance necessitates continuous infusion.
04Side Effects & Safety
Parameter
HCG
VIP
Injection site reaction
Pain, erythema (mild, transient)
—
Gynecomastia
Aromatization of elevated testosterone to estradiol; dose-dependent
—
Testicular discomfort / Edema
Rapid testicular growth in hypogonadal males; usually self-limiting
—
Polycythemia
Elevated hematocrit from supraphysiological testosterone; monitor CBC
—
Mood / Libido changes
Variable; usually positive with normalization of testosterone
—
Acne / Oily skin
Androgen-mediated; dose-dependent
—
Prostate concerns
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
—
Antibody formation
Rare with recombinant; possible with urinary-derived
—
Hypotension
—
Transient vasodilation-related blood pressure drop
Tachycardia
—
Reflex tachycardia secondary to vasodilation
Infusion site reactions
—
Erythema, phlebitis (IV administration)
GI symptoms
—
Nausea, diarrhea (VIP is endogenous GI peptide)
Overall tolerability
—
Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo
Absolute Contraindications
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
VIP
- ·Known hypersensitivity to aviptadil or formulation components
Relative Contraindications
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
VIP
- ·Severe hypotension or shock states (monitor blood pressure)
- ·Pregnancy — insufficient safety data
05Administration Protocol
Parameter
HCG
VIP
1. Reconstitution (if lyophilized)
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.
2. Injection site
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).
3. Timing
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.
5. Needle selection
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).
Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.